GlaxoSmithKline Cash vs Non Current Assets Total Analysis
GSK Stock | USD 44.77 0.75 1.70% |
GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC ADR latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC ADR is a good investment. Please check the relationship between GlaxoSmithKline PLC Cash and its Non Current Assets Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
Cash vs Non Current Assets Total
Cash vs Non Current Assets Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC ADR Cash account and Non Current Assets Total. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between GlaxoSmithKline PLC's Cash and Non Current Assets Total is 0.56. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of GlaxoSmithKline PLC ADR, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Cash and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of GlaxoSmithKline PLC ADR are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Cash i.e., GlaxoSmithKline PLC's Cash and Non Current Assets Total go up and down completely randomly.
Correlation Coefficient | 0.56 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Cash
Cash refers to the most liquid asset of GlaxoSmithKline PLC ADR, which is listed under current asset account on GlaxoSmithKline PLC ADR balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from GlaxoSmithKline PLC customers. The amounts must be unrestricted with restricted cash listed in a different GlaxoSmithKline PLC account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although Enterprise Value Over EBITDA will most likely fall to 7.90.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 784M | 879M | 775M | 502.2M | Depreciation And Amortization | 2.6B | 2.4B | 2.3B | 1.2B |
GlaxoSmithKline PLC fundamental ratios Correlations
Click cells to compare fundamentals
GlaxoSmithKline PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GlaxoSmithKline PLC fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 79.7B | 80.4B | 79.1B | 60.1B | 59.0B | 32.8B | |
Short Long Term Debt Total | 30.5B | 27.2B | 24.2B | 21.0B | 18.0B | 11.0B | |
Other Current Liab | 755M | 765M | 958M | 2.3B | 14.3B | 15.0B | |
Total Current Liabilities | 24.1B | 22.1B | 23.7B | 22.8B | 21.1B | 11.2B | |
Total Stockholder Equity | 12.0B | 14.6B | 15.1B | 10.6B | 13.3B | 14.0B | |
Property Plant And Equipment Net | 11.3B | 11.0B | 10.7B | 9.6B | 10.0B | 7.2B | |
Net Debt | 25.8B | 20.9B | 19.9B | 17.3B | 15.1B | 8.3B | |
Accounts Payable | 14.9B | 15.8B | 17.6B | 16.3B | 3.7B | 6.2B | |
Cash | 4.7B | 6.3B | 4.3B | 3.7B | 2.9B | 2.7B | |
Non Current Assets Total | 60.2B | 60.2B | 60.4B | 39.4B | 40.4B | 20.9B | |
Non Currrent Assets Other | 1.2B | 1.1B | 1.8B | 5.3B | 634M | 1.1B | |
Cash And Short Term Investments | 4.8B | 6.4B | 4.3B | 7.9B | 5.2B | 4.0B | |
Common Stock Shares Outstanding | 4.0B | 4.0B | 3.2B | 4.1B | 4.1B | 2.2B | |
Liabilities And Stockholders Equity | 79.7B | 80.4B | 79.1B | 60.1B | 59.0B | 32.8B | |
Non Current Liabilities Total | 37.3B | 37.5B | 34.1B | 27.2B | 25.1B | 14.3B | |
Inventory | 5.9B | 6.0B | 5.8B | 5.1B | 5.5B | 3.0B | |
Other Stockholder Equity | 5.2B | 4.9B | 4.9B | 5.1B | 3.2B | 2.9B | |
Total Liab | 61.3B | 59.6B | 57.8B | 50.1B | 46.2B | 25.5B | |
Property Plant And Equipment Gross | 10.3B | 11.0B | 10.7B | 9.6B | 20.2B | 21.2B | |
Total Current Assets | 19.5B | 20.2B | 18.7B | 20.8B | 18.6B | 11.9B | |
Capital Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Short Term Debt | 6.9B | 3.7B | 3.6B | 4.0B | 2.8B | 2.2B | |
Common Stock | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | |
Retained Earnings | 5.1B | 6.8B | 7.9B | 4.4B | 7.2B | 7.6B | |
Accumulated Other Comprehensive Income | 641M | 1.6B | 642M | (48M) | 1.6B | 1.7B | |
Intangible Assets | 31.0B | 29.8B | 30.1B | 14.3B | 14.8B | 11.4B | |
Other Liab | 13.7B | 14.1B | 13.5B | 10.2B | 11.7B | 14.2B | |
Long Term Debt | 22.6B | 23.4B | 20.6B | 17.0B | 14.2B | 17.5B | |
Good Will | 10.6B | 10.6B | 10.6B | 7.0B | 6.8B | 5.3B | |
Other Current Assets | 1.6B | 617M | 525M | 7.7B | 561M | 533.0M | |
Property Plant Equipment | 11.3B | 11.0B | 10.7B | 9.6B | 8.7B | 9.7B | |
Current Deferred Revenue | 1.4B | 1.8B | 1.6B | 299M | 222M | 233.1M | |
Other Assets | 5.1B | 5.3B | 6.9B | 6.9B | 7.9B | 5.4B | |
Net Receivables | 7.1B | 7.3B | 8.0B | 7.1B | 7.4B | 6.5B | |
Net Tangible Assets | (30.1B) | (25.8B) | (25.6B) | (10.8B) | (12.4B) | (13.0B) | |
Short Long Term Debt | 6.7B | 3.5B | 3.4B | 3.8B | 2.7B | 4.3B |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as GlaxoSmithKline PLC ADR using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.59 | Earnings Share 2.78 | Revenue Per Share 15.15 | Quarterly Revenue Growth 0.059 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.